Latest Tapentadol Stories
TALLAHASSEE, Fla., March 11, 2011 /PRNewswire/ -- The Florida Society of Pain Management Providers (www.Flspmp.org) releases the latest facts on Oxycodone and Hydrocodone use in the United States. Until now these statistics were not readily available to the public or media.
Company Successfully Completes Third Pivotal MoxDuo® Phase 3 Study Sydney, Australia and Bedminster, New Jersey (Vocus/PRWEB) February 21, 2011 QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the granting of a pre-New Drug Application (NDA) meeting with the United States Food and Drug Administration (FDA) and successful completion of its third pivotal Phase 3 registration trial (study 009) for immediate-release MoxDuo.
Scientists studying the benefits of pain medications said Wednesday that people who do not believe their pain drugs will work may actually reduce or even rescind the effectiveness of those drugs.
NASHVILLE, Tenn., Feb. 15, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of data from a clinical trial evaluating the pharmacokinetics, safety and tolerability of a rapid infusion of CaldolorÂ® (ibuprofen) Injection compared to oral ibuprofen.
RARITAN, N.J., Jan. 28, 2011 /PRNewswire/ -- New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.
NASHVILLE, Tenn., Jan. 27, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of data affirming the safety and efficacy of CaldolorÂ® (ibuprofen) Injection in treating post-operative pain in hospitalized patients.
Study Designed to Evaluate Side Effect and Safety Advantages of MoxDuo IR Compared to Equi-Analgesic Doses of Morphine and of Oxycodone Sydney, Australia and Bedminster, NJ (Vocus/PRWEB) January 24, 2011 QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today initiation of a Phase 3 trial (Study 022) to compare the tolerability and safety profile of MoxDuo IR to equi-analgesic doses of either morphine or oxycodone given alone.
STAMFORD, Conn., Jan. 20, 2011 /PRNewswire/ -- Butrans(TM) (buprenorphine) Transdermal System CIII from Purdue Pharma L.P.
LAS VEGAS, Jan. 4, 2011 /PRNewswire/ -- CardioVascular BioTherapeutics, Inc. (Pink Sheets: CVBT) today released summary Phase IIa and Phase IIb clinical trial data for CVBT's biological therapy to treat diabetic wounds, CVBT-141B.
NEW YORK, Nov. 7, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.
- A serpent whose bite was fabled to produce intense thirst.